|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.370 USD | 0.00% |
|
+2.60% | +31.67% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -18.06 | -12.57 | 9.32 | 3.1 | -4.41 | |||||
Return on Total Capital | -39.47 | -32.36 | 15.81 | 4.51 | -6.53 | |||||
Return On Equity % | 166.79 | 179.02 | 72.5 | 7.64 | -14.44 | |||||
Return on Common Equity | 166.79 | 179.02 | 72.5 | 7.64 | -14.44 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 57.37 | 58.87 | 64.91 | 31.27 | 13.01 | |||||
SG&A Margin | 33.19 | 24.58 | 22.84 | 22.83 | 22.15 | |||||
EBITDA Margin % | -50.44 | -25.04 | 17.79 | 9.78 | -7.65 | |||||
EBITA Margin % | -53.36 | -27.32 | 15.97 | 7.34 | -10.43 | |||||
EBIT Margin % | -53.36 | -27.32 | 15.97 | 7.34 | -10.43 | |||||
Income From Continuing Operations Margin % | -71.92 | -31.33 | 12.69 | 5.49 | -12.52 | |||||
Net Income Margin % | -71.92 | -31.33 | 12.69 | 5.49 | -12.52 | |||||
Net Avail. For Common Margin % | -71.92 | -31.33 | 12.69 | 5.49 | -12.52 | |||||
Normalized Net Income Margin | -43.6 | -18.89 | 8.17 | 4.86 | -6.65 | |||||
Levered Free Cash Flow Margin | -31.53 | -15.85 | -2.76 | 10.18 | -23.12 | |||||
Unlevered Free Cash Flow Margin | -28.24 | -13.16 | -0.13 | 11.42 | -21.71 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.54 | 0.74 | 0.93 | 0.68 | 0.68 | |||||
Fixed Assets Turnover | 3.77 | 4.87 | 6.38 | 5.11 | 4.67 | |||||
Receivables Turnover (Average Receivables) | 14.09 | 11.87 | 13.29 | 13.05 | 8.98 | |||||
Inventory Turnover (Average Inventory) | 1.05 | 1.13 | 1.28 | 1.82 | 1.95 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.86 | 1.38 | 1.54 | 2.34 | 2.51 | |||||
Quick Ratio | 1.29 | 0.84 | 1.11 | 1.49 | 1.5 | |||||
Operating Cash Flow to Current Liabilities | -0.31 | -0.77 | -0.03 | 0.34 | -0.45 | |||||
Days Sales Outstanding (Average Receivables) | 25.9 | 30.75 | 27.47 | 28.04 | 40.65 | |||||
Days Outstanding Inventory (Average Inventory) | 346.45 | 323.77 | 284.68 | 200.89 | 186.84 | |||||
Average Days Payable Outstanding | 122.18 | 127.14 | 73.67 | 41.65 | 35.48 | |||||
Cash Conversion Cycle (Average Days) | 250.16 | 227.38 | 238.47 | 187.28 | 192.01 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -554.51 | -314.61 | 78.29 | 12.79 | 17.25 | |||||
Total Debt / Total Capital | 122 | 146.6 | 43.91 | 11.34 | 14.71 | |||||
LT Debt/Equity | -534.51 | -304.1 | 13.77 | 9.32 | 14.38 | |||||
Long-Term Debt / Total Capital | 117.6 | 141.7 | 7.72 | 8.26 | 12.27 | |||||
Total Liabilities / Total Assets | 108.19 | 119.07 | 60.24 | 41.14 | 41.43 | |||||
EBIT / Interest Expense | -3.25 | -5.15 | 3.29 | 3.69 | -4.62 | |||||
EBITDA / Interest Expense | -2.81 | -4.16 | 4.13 | 6.46 | -1.86 | |||||
(EBITDA - Capex) / Interest Expense | -3.05 | -4.41 | 3.77 | 5.25 | -3.24 | |||||
Total Debt / EBITDA | -1.89 | -3.18 | 2 | 0.81 | -3.75 | |||||
Net Debt / EBITDA | 0.31 | -1.07 | -1.39 | -4.27 | 9.89 | |||||
Total Debt / (EBITDA - Capex) | -1.75 | -3 | 2.2 | 0.99 | -2.16 | |||||
Net Debt / (EBITDA - Capex) | 0.29 | -1.01 | -1.53 | -5.25 | 5.69 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -39.03 | 24.22 | 37.48 | -18.47 | -1.23 | |||||
Gross Profit, 1 Yr. Growth % | -57.71 | 27.48 | 51.58 | -36.25 | -58.91 | |||||
EBITDA, 1 Yr. Growth % | -582.15 | -38.34 | -197.68 | -55.19 | -177.28 | |||||
EBITA, 1 Yr. Growth % | -855.06 | -36.4 | -180.37 | -62.55 | -240.41 | |||||
EBIT, 1 Yr. Growth % | -855.06 | -36.4 | -180.37 | -62.55 | -240.41 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 322.84 | -45.88 | -155.68 | -64.73 | -325.24 | |||||
Net Income, 1 Yr. Growth % | 322.84 | -45.88 | -155.68 | -64.73 | -325.24 | |||||
Normalized Net Income, 1 Yr. Growth % | 310.1 | -47.8 | -159.5 | -51.51 | -235 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 179.22 | -50.72 | -127.96 | -57.71 | -329.39 | |||||
Accounts Receivable, 1 Yr. Growth % | 72.1 | 33.24 | 14.96 | -44.82 | 203.88 | |||||
Inventory, 1 Yr. Growth % | 37.24 | -6.41 | 13.34 | 11.54 | 21.12 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.71 | -2.84 | 12.88 | -7.91 | 25.53 | |||||
Total Assets, 1 Yr. Growth % | 8.44 | -24.27 | 51.35 | -13.05 | 12.16 | |||||
Tangible Book Value, 1 Yr. Growth % | -77.68 | 76.28 | -415.5 | 28.72 | 11.62 | |||||
Common Equity, 1 Yr. Growth % | -77.68 | 76.28 | -415.5 | 28.72 | 11.62 | |||||
Cash From Operations, 1 Yr. Growth % | -60.6 | 143.07 | -94.73 | -758.12 | -238.26 | |||||
Capital Expenditures, 1 Yr. Growth % | 122.75 | -56.96 | 82.96 | 11.58 | 27.77 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 82.31 | -41.29 | -76.07 | -400.91 | -324.44 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 107.54 | -42.12 | -98.64 | -7.23K | -287.8 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -16.26 | -12.97 | 30.68 | 5.87 | -10.26 | |||||
Gross Profit, 2 Yr. CAGR % | -29.12 | -26.58 | 39.01 | 361.22 | -48.82 | |||||
EBITDA, 2 Yr. CAGR % | 45.8 | 72.43 | -22.39 | -33.84 | -41.15 | |||||
EBITA, 2 Yr. CAGR % | 38.18 | 119.14 | -28.5 | -45.14 | -27.49 | |||||
EBIT, 2 Yr. CAGR % | 38.18 | 119.14 | -28.5 | -45.14 | -27.49 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 22.85 | 51.27 | -45.1 | -55.68 | -10.86 | |||||
Net Income, 2 Yr. CAGR % | 22.85 | 51.27 | -45.1 | -55.68 | -10.86 | |||||
Normalized Net Income, 2 Yr. CAGR % | 20.98 | 48.56 | -44.27 | -46.28 | -19.09 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -28.77 | 17.31 | -62.76 | -65.61 | -1.51 | |||||
Accounts Receivable, 2 Yr. CAGR % | -14.42 | 51.43 | 23.76 | -20.36 | 29.49 | |||||
Inventory, 2 Yr. CAGR % | 48.38 | 13.34 | 2.99 | 12.44 | 16.23 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -4.81 | -3.78 | 4.73 | 1.96 | 7.51 | |||||
Total Assets, 2 Yr. CAGR % | 27.39 | -9.38 | 7.06 | 14.72 | -1.24 | |||||
Tangible Book Value, 2 Yr. CAGR % | -70.7 | -37.27 | 135.83 | 101.52 | 19.86 | |||||
Common Equity, 2 Yr. CAGR % | -70.7 | -37.27 | 135.83 | 101.52 | 19.86 | |||||
Cash From Operations, 2 Yr. CAGR % | -27.11 | -2.14 | -64.2 | -41.1 | 201.65 | |||||
Capital Expenditures, 2 Yr. CAGR % | 52.54 | -2.08 | -11.26 | 42.88 | 19.4 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 88.48 | -1.58 | -62.52 | -15.15 | 159.88 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 47.22 | 9.6 | -91.12 | -1.36 | 1.06K | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 3.85 | -4.5 | 1.36 | 11.67 | 3.45 | |||||
Gross Profit, 3 Yr. CAGR % | -4.09 | -13.81 | -6.51 | -8.78 | 106 | |||||
EBITDA, 3 Yr. CAGR % | 3.13 | 9.44 | 42.67 | -35.37 | -30.32 | |||||
EBITA, 3 Yr. CAGR % | 1.95 | 6.69 | 56.86 | -42.37 | -24.96 | |||||
EBIT, 3 Yr. CAGR % | 1.95 | 6.69 | 56.86 | -42.37 | -24.96 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 1.4 | -6.52 | 8.41 | -52.63 | -23.8 | |||||
Net Income, 3 Yr. CAGR % | 1.4 | -6.52 | 8.41 | -52.63 | -23.8 | |||||
Normalized Net Income, 3 Yr. CAGR % | 0.33 | -7.64 | 9.51 | -46.8 | -26.97 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -29.69 | -37 | -27.11 | -61.15 | -35.27 | |||||
Accounts Receivable, 3 Yr. CAGR % | -10.05 | -0.82 | 38.14 | -5.45 | 24.45 | |||||
Inventory, 3 Yr. CAGR % | 27.96 | 27.25 | 13.34 | 5.77 | 15.26 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 15.8 | -4.16 | 1.48 | 0.33 | 9.28 | |||||
Total Assets, 3 Yr. CAGR % | 6.41 | 7.12 | 7.52 | -0.11 | 13.86 | |||||
Tangible Book Value, 3 Yr. CAGR % | -51.49 | -46.71 | 7.48 | 92.73 | 65.5 | |||||
Common Equity, 3 Yr. CAGR % | -51.49 | -46.71 | 7.48 | 92.73 | 65.5 | |||||
Cash From Operations, 3 Yr. CAGR % | 9.93 | 8.9 | -63.04 | -5.52 | -21.72 | |||||
Capital Expenditures, 3 Yr. CAGR % | 28.6 | 0.05 | 20.6 | -4.22 | 37.65 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.15 | 30.41 | -38.58 | -24.95 | 17.35 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 23.61 | 7.85 | -74.6 | -17.42 | 22.25 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 33.05 | 17.71 | 13.85 | -0.48 | -3.46 | |||||
Gross Profit, 5 Yr. CAGR % | 93.98 | 36.83 | 11.26 | -17.54 | -33.31 | |||||
EBITDA, 5 Yr. CAGR % | -9.11 | -18.21 | -7.96 | -10.52 | 0.11 | |||||
EBITA, 5 Yr. CAGR % | -9.21 | -17.72 | -11.54 | -18.23 | 15.21 | |||||
EBIT, 5 Yr. CAGR % | -9.21 | -17.72 | -11.54 | -18.23 | 15.21 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -1.12 | -29.12 | -20.67 | -30.65 | 0.25 | |||||
Net Income, 5 Yr. CAGR % | -1.24 | -29.12 | -20.67 | -30.65 | 0.25 | |||||
Normalized Net Income, 5 Yr. CAGR % | -9.16 | -29.41 | -20.21 | -25.64 | -2.98 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -26.32 | -45.43 | -45.47 | -50.49 | -17.78 | |||||
Accounts Receivable, 5 Yr. CAGR % | 37.79 | 21.66 | 2.2 | -9.15 | 34.61 | |||||
Inventory, 5 Yr. CAGR % | 27.9 | 16.49 | 17.32 | 21.1 | 14.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 2.66 | 4.66 | 11.24 | -1.76 | 3.85 | |||||
Total Assets, 5 Yr. CAGR % | -2.18 | -5.03 | 6.67 | 10.09 | 3.92 | |||||
Tangible Book Value, 5 Yr. CAGR % | -9.53 | -18.43 | -8.69 | -9.28 | 12.27 | |||||
Common Equity, 5 Yr. CAGR % | -9.53 | -18.43 | -8.69 | -9.28 | 12.27 | |||||
Cash From Operations, 5 Yr. CAGR % | -20.36 | 20.13 | -29.82 | -14.83 | -14.41 | |||||
Capital Expenditures, 5 Yr. CAGR % | 11.44 | -8.35 | 10.87 | 15.38 | 20.12 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -8.06 | -20.26 | -25.2 | 9.81 | 9.37 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -8.16 | -19.64 | -56.88 | 4.06 | 17.02 |
- Stock Market
- Stocks
- PLX Stock
- Financials Protalix BioTherapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















